Cargando…

Bortezomib, a Proteasome Inhibitor, Attenuates Angiotensin II-Induced Hypertension and Aortic Remodeling in Rats

BACKGROUND: Hypertension is a highly prevalent disorder and a major risk factor for cardiovascular diseases. Hypertensive vascular remodeling is the pathological mal-adaption of blood vessels to the hypertensive condition that contributes to further development of high blood pressure and end-organ d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Shuai, Wang, Xuejun, Li, Yifan, Kost, Curtis K., Martin, Douglas S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813683/ https://www.ncbi.nlm.nih.gov/pubmed/24205262 http://dx.doi.org/10.1371/journal.pone.0078564

Ejemplares similares

Inhibition of Proteasome Activity by Low-dose Bortezomib Attenuates Angiotensin II-induced Abdominal Aortic Aneurysm in Apo E(−/−) Mice
por: Ren, Hualiang, et al.
Publicado: (2015)

The resistance mechanisms of proteasome inhibitor bortezomib
por: Lü, Shuqing, et al.
Publicado: (2013)

The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-β1
por: Zeniya, Moko, et al.
Publicado: (2017)

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
por: Boccadoro, Mario, et al.
Publicado: (2005)

Proteasome Inhibitor Bortezomib Ameliorates Intestinal Injury in Mice
por: Yanaba, Koichi, et al.
Publicado: (2012)

Alterations of the Intracellular Peptidome in Response to the Proteasome Inhibitor Bortezomib
por: Gelman, Julia S., et al.
Publicado: (2013)

Angiotensin II receptor blocker telmisartan attenuates aortic stiffening and remodelling in STZ-diabetic rats
por: Salum, Erik, et al.
Publicado: (2014)

Trypanocidal activity of the proteasome inhibitor and anti-cancer drug bortezomib
por: Steverding, Dietmar, et al.
Publicado: (2009)

Metformin Induces Resistance of Cancer Cells to the Proteasome Inhibitor Bortezomib
por: Schlesser, Camille, et al.
Publicado: (2022)

Cardiomyocyte-specific deletion of TLR4 attenuates angiotensin II-induced hypertension and cardiac remodeling
por: Theobald, Drew, et al.
Publicado: (2023)

Local Application of Leptin Antagonist Attenuates Angiotensin II–Induced Ascending Aortic Aneurysm and Cardiac Remodeling
por: Ben‐Zvi, Danny, et al.
Publicado: (2016)

Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure()
por: Pitcher, David S., et al.
Publicado: (2015)

Effect of the specific proteasome inhibitor bortezomib on cancer‐related muscle wasting
por: Penna, Fabio, et al.
Publicado: (2015)

Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling
por: Accardi, Fabrizio, et al.
Publicado: (2015)

Histone deacetylase inhibitor LMK235 attenuates vascular constriction and aortic remodelling in hypertension
por: Choi, Sin Young, et al.
Publicado: (2019)

Neohesperidin Protects Angiotensin II-Induced Hypertension and Vascular Remodeling
por: Zhang, Jingsi, et al.
Publicado: (2022)

Deletion of Superoxide Dismutase 1 Blunted Inflammatory Aortic Remodeling in Hypertensive Mice under Angiotensin II Infusion
por: Shiraishi, Yasunaga, et al.
Publicado: (2021)

Proteasome inhibition reduces plasma cell and antibody secretion, but not angiotensin II-induced hypertension
por: Figueiredo Galvao, Hericka Bruna, et al.
Publicado: (2023)

The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis
por: van Dijk, Marianne, et al.
Publicado: (2011)

Hypoxia Enhances the Senescence Effect of Bortezomib—The Proteasome Inhibitor—On Human Skin Fibroblasts
por: Krętowski, Rafał, et al.
Publicado: (2014)

Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone
por: Erath, Alexandra, et al.
Publicado: (2020)

The Proteasome Inhibitor Bortezomib Induces Apoptosis and Activation in Gel-Filtered Human Platelets
por: Ghansah, Harriet, et al.
Publicado: (2021)

Upregulation of Protein Synthesis and Proteasome Degradation Confers Sensitivity to Proteasome Inhibitor Bortezomib in Myc-Atypical Teratoid/Rhabdoid Tumors
por: Tran, Huy Minh, et al.
Publicado: (2020)

Effect of Lysyl Oxidase Inhibition on Angiotensin II-Induced Arterial Hypertension, Remodeling, and Stiffness
por: Eberson, Lance S., et al.
Publicado: (2015)

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P G, et al.
Publicado: (2017)

Angiotensin Receptor‐Neprilysin Inhibition Attenuates Right Ventricular Remodeling in Pulmonary Hypertension
por: Sharifi Kia, Danial, et al.
Publicado: (2020)

Structural basis to repurpose boron-based proteasome inhibitors Bortezomib and Ixazomib as β-lactamase inhibitors
por: Perbandt, Markus, et al.
Publicado: (2022)

TRIM28 attenuates Bortezomib sensitivity of hepatocellular carcinoma cells through enhanced proteasome expression
por: Zhang, Jianchao, et al.
Publicado: (2022)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

HDAC Inhibitor L-Carnitine and Proteasome Inhibitor Bortezomib Synergistically Exert Anti-Tumor Activity In Vitro and In Vivo
por: Huang, Hongbiao, et al.
Publicado: (2012)

Adventitial gene transfer of catalase attenuates angiotensin II-induced vascular remodeling
por: LIU, CUN-FEI, et al.
Publicado: (2015)

Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL(3)B
por: Reynolds, Jennifer M, et al.
Publicado: (2007)

Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs
por: MUJTABA, TASKEEN, et al.
Publicado: (2012)

Analysis of bortezomib inhibitor docked within the catalytic subunits of the Plasmodium falciparum 20S proteasome
por: Sridhar, Settu, et al.
Publicado: (2013)

The Protective Effects of the Proteasome Inhibitor Bortezomib (Velcade) on Ischemia-Reperfusion Injury in the Rat Retina
por: Chen, Fang-Ting, et al.
Publicado: (2013)

Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response
por: Nikesitch, N, et al.
Publicado: (2016)

Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer
por: Taromi, Sanaz, et al.
Publicado: (2017)

In situ Electrochemical Evaluation of the Interaction of dsDNA with the Proteasome Inhibitor Anticancer Drug Bortezomib
por: Bunea, Mihaela-Cristina, et al.
Publicado: (2023)

Calcium/Calmodulin-Dependent Kinase II Inhibition in Smooth Muscle Reduces Angiotensin II–Induced Hypertension by Controlling Aortic Remodeling and Baroreceptor Function
por: Prasad, Anand M, et al.
Publicado: (2015)

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P. G., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_idquht0355tkbgj949eqeb2u0f